To study the effects on adjuvant therapy in patients with sarcomatoid RCC enrolled in the randomized phase 3 clinical trial E2805.
The original trial (E2805) is a randomized, double-blinded phase 3 clinical trial comparing outcomes in 1,943 patients with RCC accrued between 2006 and 2010, and treated with up to 1 year of adjuvant placebo, sunitinib, or sorafenib.